Please login to the form below

Not currently logged in
Email:
Password:

Merck enters Alzheimer's partnership

Merck has entered into a $289m research partnership with Alectos Therapeutics

Merck has entered into a research partnership with Alectos Therapeutics focused on compounds that modulate the enzyme -linked N-acetylglucosaminidase (O-GlcNAcase).

The deal, which is valued at $289m, gives Merck exclusive global rights to research, develop and commercialise compounds that modulate the target in return for an upfront payment, milestones, royalties, and research funding for Alectos' existing portfolio of compounds targeting Alzheimer's disease. 

The agreement calls for Alectos and Merck to partner on discovery and preclinical development, with Merck taking over full responsibility for clinical development. The companies may also develop products that modulate the enzyme as treatments for other neurological diseases.

Alectos was founded by researchers from Canada's Simon Frasier University.

11th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics